

CITATION REPORT

List of articles citing

Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure

DOI: 10.1016/j.clpt.2004.06.003

Clinical Pharmacology and Therapeutics, 2004, 76, 371-8.

Source: <https://exaly.com/paper-pdf/37216579/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Effects of sildenafil on hypoxic pulmonary vascular function in dogs. <i>Journal of Applied Physiology</i> , 2006 , 101, 1085-90	3.7	28
31	Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. <i>BJU International</i> , 2006 , 97, 625-33	5.6	98
30	The effect of vardenafil on endothelial function of brachial and cavernous arteries. <i>International Journal of Impotence Research</i> , 2006 , 18, 464-9	2.3	32
29	Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. <i>Journal of Gastroenterology</i> , 2006 , 41, 593-7	6.9	31
28	The emerging role for type 5 phosphodiesterase inhibition in heart failure. <i>Current Heart Failure Reports</i> , 2006 , 3, 123-8	2.8	12
27	Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. <i>Journal of Sexual Medicine</i> , 2006 , 3, 84-94; discussion 94-5	1.1	28
26	Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. <i>Circulation</i> , 2007 , 115, 59-66	16.7	285
25	Sildenafil analogs used for adulterating marijuana. <i>Forensic Science International</i> , 2008 , 182, e23-4	2.6	8
24	Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 336-41	6.1	36
23	Sildenafil improves the alveolar-capillary function in heart failure patients. <i>International Journal of Cardiology</i> , 2008 , 126, 68-72	3.2	13
22	Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. <i>European Heart Journal</i> , 2008 , 29, 1681-7	9.5	177
21	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. <i>Nature Reviews Cardiology</i> , 2009 , 6, 349-55	14.8	25
20	Treating heart failure with sildenafil. <i>Congestive Heart Failure</i> , 2009 , 15, 181-5		10
19	Relation of systemic venous return, pulmonary vascular resistance, and diastolic dysfunction to exercise capacity in patients with single ventricle receiving fontan palliation. <i>American Journal of Cardiology</i> , 2010 , 105, 1169-75	3	64
18	Pulmonary hypertension in heart failure. <i>Journal of Cardiac Failure</i> , 2010 , 16, 461-74	3.3	63
17	Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. <i>Annals of Pharmacotherapy</i> , 2011 , 45, 1551-8	2.9	11
16	Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. <i>Current Heart Failure Reports</i> , 2011 , 8, 219-25	2.8	2

15	Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. <i>Future Cardiology</i> , 2011 , 7, 609-12	1.3	9
14	Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction. <i>Pulmonary Circulation</i> , 2012 , 2, 163-9	2.7	18
13	World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 913-33	5.8	165
12	Modulation of pulmonary vascular resistance as a target for therapeutic interventions in Fontan patients: focus on phosphodiesterase inhibitors. <i>Future Cardiology</i> , 2012 , 8, 271-84	1.3	23
11	Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. <i>European Journal of Applied Physiology</i> , 2012 , 112, 1285-94	3.4	15
10	Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure. <i>Journal of Cardiac Failure</i> , 2013 , 19, 712-21	3.3	14
9	The Endothelium-Dependent Nitric Oxide-cGMP Pathway. <i>Advances in Pharmacology</i> , 2016 , 77, 1-27	5.7	45
8	The influence of pulmonary vascular pressures on lung diffusing capacity during incremental exercise in healthy aging. <i>Physiological Reports</i> , 2018 , 6, e13565	2.6	7
7	Clinical and hemodynamic effects of oral sildenafil on biventricular function on patients with left ventricular systolic dysfunction. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14171	2.9	0
6	The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure. <i>Korean Journal of Pediatrics</i> , 2016 , 59, 262-70	2.4	10
5	Heart Failure. 2010 , 1036-1053		
4	Pulmonary Hypertension in Left Heart Disease. 2017 , 341-369		
3	Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. <i>Meditsinskiy Sovet</i> , 2019 , 192-202	0.4	
2	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. <i>Core Evidence</i> , 2008 , 2, 225-31	4.9	2
1	Relationship of arterial tonometry and exercise in patients with chronic heart failure: a systematic review with meta-analysis and trial sequential analysis. 2022 , 22,		1